Fiscal Year Ending December 2026, Third Quarter Financial Summary (Japanese GAAP) (Consolidated)

Performance Overview

For the consolidated cumulative third quarter of this fiscal year, revenue was 19,730 million yen (Year-over-Year +31.6%), operating income was 6,696 million yen (YoY +57.6%), ordinary income was 6,797 million yen (YoY +55.8%), and net income attributable to owners of parent for the quarter was 4,823 million yen (YoY +44.9%), representing substantial increases. Revenue growth was driven mainly by pharmaceuticals, with an overseas ratio maintained at a high level of 68.0%. According to supplementary explanations, demand related to AI has expanded, supporting steady product demand. By segment, revenue and profits expanded across regions including Japan, Taiwan, Zhuhai, Suzhou, Europe and Thailand. The full-year forecasts have been raised to revenue 26,500 million yen, operating income 8,600 million yen, and net income attributable to owners of parent 6,100 million yen.

Outlook and Dividends

The financial summary states that full-year performance forecasts have been revised, with revenue expected at 26,500 million yen, operating income at 8,600 million yen, and net income at 6,100 million yen. Earnings per share is 334.05 yen. The overseas sales ratio remains at a high level, and under the Phase 2 medium-term management plan (FY2025–FY2027) the Company will accelerate digitalization and green initiatives. An earnings presentation for institutional investors and analysts is scheduled for November 11, and the materials will be posted on the website.